T1	Participants 61 98	acute myelogenous leukemia in relapse
T2	Participants 130 331	Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses
T3	Participants 514 525	25 patients
T4	Participants 566 568	23
